OXIGENE (OXGN) Rips After Geting SPA From FDA for ZYBRESTAT Phase 3
Article
Related Press Releases (1)
Related Articles (1)
Related SEC Filings (1)
Stock Quotes (1)
Comments (0)
Tweet
Send to a Friend
OXIGENE (Nasdaq: OXGN) shares are popping higher in late trading Monday after announcing it came to a Special Protocol Assessment (SPA) with the FDA for its Phase 3 clinical trial (FACT 2) of ZYBRESTAT for the treatment of anaplastic thyroid cancer (ATC).
Shares are up over 18 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares are up over 18 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Herbalife (HLF) Sees Intra-Day Pressure
- UPDATE: MannKind Corp. (MNKD) Crashes
- Orchard Supply (OSH) Sees Complete Loss of Equityholder Investment in Ch. 11 Proceedings
Create E-mail Alert Related Categories
FDA, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
